Knowledge Library
AACR 2024 Posters: Sneak Peek
AACR 2024 Sneak Peek | Your All-In-One Guide to WuXi Biology’s Latest Advances in Cancer Research The American Association for Cancer Research (AACR) Annual Meeting 2024, one of the largest global cancer research conferences, will take place from April 5 to 10 at the San Diego Convention Center. This year, WuXi Biology has been selected …Read More >
Pioneering Advanced Modalities in Early Drug Discovery
New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving needs, WuXi Biology has proactively developed a broad range of capabilities, offering integrated solutions to global pharmaceutical and biotech companies for challenging targets. We have established major capabilities for new modalities in the early discovery …Read More >
Oncolytic Virus Platform
Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity. WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity assays, …Read More >
Discovery Newsletter November 2022
Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses
While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. …Read More >
WuXi AppTec Discovery Services
Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.
Cell Line-Derived Xenograft (CDX) Tumor Models
A large collection of cell line-derived xenograft (CDX) tumor models 215 validated models, SOC data available World leading imaging based orthotopic/metastatic CDX platform 28 models covering 16 tumor types
Virology and Viral Vector Platforms
WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy clinical virology Liver-specific viruses | Respiratory viruses | Herpes viruses | Other viruses
Clinical Virology
Clinical Virology and Advanced Therapy Platforms Research Services: CAP Accredited Molecular Testing Laboratory Genetics and Biomarker Platform HBV Genotyping Assays HBV Serology Assays HBV Phenotyping Assays Immunological Assays Other Assays: Oncolytic | CAR-T/TCR-T Particular Solutions Clinical virology: Viral load, sequencing, genotyping, TCID50, phenotyping, virus isolation and characterization, serology Vaccines: Advanced therapies (Viral vector and cell therapies): …Read More >